Clinical Trial Detail

NCT ID NCT01775501
Title Sorafenib + mFOLFOX for Hepatocellular Carcinoma
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements no
Sponsors Massachusetts General Hospital
Indications

hepatocellular carcinoma

Therapies

Sorafenib

Fluorouracil

Oxaliplatin

Leucovorin

Age Groups: adult

No variant requirements are available.